The synthetic peptides p195-212 and p259-271, representing amino acids 195-212 and 259-271 of the ar subunit of the human acetylcholine receptor, preferentially stimulate T cells of patients with myasthenia gravis and are immunodominant T-celi epitopes in SJL and BALB/c mice, respectively. We designed and synthesized analogs of these peptides that contain single amino acid substitutions. An analog of peptide p195-212, no. 455 (Met-207 -* Ala), was capable of inhibiting up to 100% of the proliferative responses of a pl95-212-specific T-cell line originating from the highresponder strain SJL. Similarly, an analog of p259-271, no.
Myasthenia gravis (MG) is a well-characterized autoimmune disorder, the symptoms of which are caused by an antibodymediated autoimmune response to the nicotinic acetylcholine receptor (AChR) (1). Although the presence of pathogenic autoantibodies was once considered to be crucial to the development of MG, several lines of experimental evidence indicate that T cells play an important role in mediating this disease (2-6). Nevertheless, it is still unclear what initiates and regulates autoimmune reactivity in MG, and there is no definitive cure for this disease (1). The higher frequency of certain histocompatibility antigens (HLA-B8 and -DR3) in MG patients (7) suggests a defect of immunoregulation that might be expressed on the level of T cells.
Previous studies showed that two peptides, p195-212 and p259-271, representing amino acids 195-212 and 257-269 of the human AChR a subunit significantly stimulated peripheral blood lymphocytes of MG patients in comparison to healthy controls. In addition, a correlation was demonstrated between the capacity of peripheral blood lymphocytes of MG patients to proliferate in response to p195-212 and p257-269 and to HLA-DR5 and HLA-DR3, respectively (8) . Extension of this research using inbred mouse strains revealed that p195-212 and p259-271 are immunodominant T-cell epitopes
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for SJL and BALB/c mice, respectively, and are cryptic epitopes for C3H.SW mice (9) .
T-cell lines and clones specific for p195-212 were established from lymph node cells oflow (C3H.SW) and high (SJL) responder mouse strains. Similarly, T-cell lines and clones specific to p259-271 were developed from LN cells of low (C3H.SW) and high (BALB/c) responder origin. Cells of the p195-212-specific SJL line (TCSJL195-212) and of the p259-271-specific BALB/c line (TCBALB/c259-271) were inoculated into naive syngeneic mice and were found to induce autoimmune responses that were manifested by the presence of anti-AChR antibodies and compound muscle actionpotential decrements (S.L.K., Y.K.-L., Y. Wirguin, and E.M., unpublished data).
T cells recognize a bimolecular ligand composed of an antigen, usually in a processed form, and self major histocompatibility complex (MHC) gene products on the surface of antigen-presenting cells. Our laboratory has established an assay for binding of peptides to live antigen-presenting cells. This assay demonstrated that p195-212 and p259-271 could bind directly to MHC class II molecules on fresh viable antigen-presenting cells from several different mouse strains (10) .
It has been proposed that T-cell responses may be inhibited by peptides that bind to MHC class II restriction elements but that do not activate specific T cells. Such inhibitory peptides may be used to specifically treat autoimmune diseases by inhibiting the pathogenic T-cell responses (11) (12) (13) (14) . For the present study we have designed and synthesized a number of analogs of p195-212 and p259-271 containing single amino acid substitutions. These analogs were screened for their ability to inhibit T-cell responses to p195-212 and p259-271 both in vitro and in vivo. Table 1 .
Since analogs 455 and 306 were found to be nonstimulatory to the TCSJL195-212 and TCBALB/c259-217 lines, respectively, their ability to inhibit the specific proliferative responses of these lines was tested. In Fig. 3 , it can be seen that Fig. 4 .
It was of interest to determine whether the analogs were capable of inhibiting a T-cell population more heterogeneous than the long-term cultures. To this end, the analogs were used to inhibit peptide-primed lymph node cells in an in vitro proliferative assay. Table 2 of the lymph node cells triggered by concanavalin A, suggesting that the inhibition was specific for the immune response elicited by p259-271.
In Vivo Inhibition of Priming of Lymph Node Cells. After determining that analogs 455 and 306 could inhibit T-cell proliferative responses in vitro, we tested their ability to inhibit in vivo priming of lymph node cells. To this end, mice were immunized intradermally with the parent peptides in complete Freund's adjuvant concomitant with aqueous administration, either i.p. or i.v., ofthe analogs. Thereafter, the proliferative capacity of the lymph node cells in response to the parent peptides was tested in vitro. Because p199-212 was often more efficient than p195-212 at priming lymph node cells, the following studies were performed with p199-212. In 
DISCUSSION
The main finding presented in this paper is that single amino acid substitutions in the myasthenogenic T-cell epitopes p195-212 and p259-271 produced peptide analogs that were able to modulate T-cell responses both in vitro and in vivo. Both p195-212 and p259-271 have been shown to be important T-cell epitopes in MG patients and immunodominant T-cell epitopes in certain mouse strains (8, 9) .
The results from a number of studies suggest that within T-cell epitopes, certain residues act as T-cell receptor (TCR) contact sites and others as MHC contact sites (18) (19) (20) (21) . With this in mind, we designed and synthesized peptidic analogs of p195-212 and p259-271 with single amino acid substitutions. The p195-212 analog that we report here, analog 455, con- Proc. Natl. Acad. Sci. USA 90 (1993) Proc. Natl. Acad. Sci. USA 90 (1993) 7003 tively, the analogs may stimulate short-term clonal competition in the lymph nodes.
It is generally believed that the mechanism of action of inhibitory peptides is through direct competition for the MHC binding site. Consistent with this, our laboratory previously reported that the p195-212-and p259-271-specific proliferative responses of T-cell lines from low-responder mouse strains could be inhibited by synthetic peptides specific for their MHC class II restriction elements (9) ution, leading to a switch from a negative charge log of an encephalogenic T-cell epitope, which had greater re charge and an increase in the size of the side affinity than did the arthritogenic analog for the same MHC restriction element, had no effect on the induction of adjuvant reviously reported from our laboratory that the arthritis. Thus, their study supports the hypothesis that e responses of p195-212-specific and p259-271-mechanisms other than MHC blockade alone play a role in cell lines originating from the low-responder inhibiting activation of pathogenic T cells. Moreover, this mi C3H.SW were inhibited up to 91% by peptides inhibition is best achieved by analogs closely related in *their MHC restriction element (9) Ioes the peptide-specific T-cell line. Nevertheless,
The ability of analogs 455 and 306 to inhibit specific T-cell )f analog 306 to inhibit up to 66% of the proliferresponses, both in vitro and in vivo, indicates that they are nses of primed lymph node cells suggests that good candidates for specific immunomodulatory therapy for 2 is important for T-cell stimulation ( (Figs. 5 and  6 ). Several possible mechanisms may be considered whereby a single administration of the analogs 455 and 306 at a stimulator/inhibitor ratio of 1:10 was sufficient to inhibit up to 80%o of the in vivo priming by both p195-212 and p259-271. One possibility is the induction of tolerance by the analogs. This does not seem likely since the analogs were not administered in a form conducive to tolerance induction (27, 28) . Another possible explanation is that the analogs may stimulate specific suppressor mechanisms in the mice. Alterna- It was pi proliferativ specific Tmouse strai specific for in vitro stu4 T-cell proli could be i included sy (11) (12) (13) (14) 
